Literature DB >> 10810999

The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity.

S R Clarke1.   

Abstract

Control of virus infections and eradication of tumors usually involves the lytic activity of CD8+ cytotoxic T lymphocytes (CTLs). The induction of effective CTL immunity relies on several factors, one of the most important of which is CD4+ T cell help. Numerous studies have demonstrated the dependence of CTL priming on the presence of CD4+ T cells, but until recently little was known of the mechanisms regulating this process. Based on reports that CD4+ and CD8+ T cells must recognize antigen on the same antigen-presenting cell (APC), help was originally thought to be provided through the delivery of short-range, CD4+ T cell-secreted cytokines. However, the results of subsequent studies favor an alternative mechanism, whereby CD4+ T cells modify the APC, converting it into a stimulatory cell for CD8+ T cell priming. It is important that CD40 and its ligand, CD40L, have been implicated in the provision of this help and, in particular, the generation of long-lasting CTL memory.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810999     DOI: 10.1002/jlb.67.5.607

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  30 in total

Review 1.  Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

2.  Deregulated expression of CD40 ligand in HTLV-I infection: distinct mechanisms of downregulation in HTLV-I-transformed cell lines and ATL patients.

Authors:  Nicole S Harhaj; Branislava Janic; Juan C Ramos; William J Harrington; Edward W Harhaj
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

3.  Inflammatory spleen monocytes can upregulate CD11c expression without converting into dendritic cells.

Authors:  Scott B Drutman; Julia C Kendall; E Sergio Trombetta
Journal:  J Immunol       Date:  2012-03-21       Impact factor: 5.422

4.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Authors:  Kevin J Curran; Beatrijs A Seinstra; Yan Nikhamin; Raymond Yeh; Yelena Usachenko; Dayenne G van Leeuwen; Terence Purdon; Hollie J Pegram; Renier J Brentjens
Journal:  Mol Ther       Date:  2015-01-13       Impact factor: 11.454

Review 5.  The tug-of-war between dendritic cells and human chronic viruses.

Authors:  Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

6.  CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.

Authors:  Matthew W Auten; Weitao Huang; Guixiang Dai; Alistair J Ramsay
Journal:  Vaccine       Date:  2012-02-18       Impact factor: 3.641

7.  CD8+ T cells complement antibodies in protecting against yellow fever virus.

Authors:  Maria R Bassi; Michael Kongsgaard; Maria A Steffensen; Christina Fenger; Michael Rasmussen; Karsten Skjødt; Bente Finsen; Anette Stryhn; Søren Buus; Jan P Christensen; Allan R Thomsen
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

8.  Detection of CD4(+)- and CD8(+)-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release.

Authors:  Jane C Steele; Sally Roberts; Susan M Rookes; Phillip H Gallimore
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 9.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

Review 10.  Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?

Authors:  A Boasso; G M Shearer; C Chougnet
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.